
UNC2025 2HCl
CAS No. ——
UNC2025 2HCl ( —— )
Catalog No. M17708 CAS No. ——
UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 101 | Get Quote |
![]() ![]() |
10MG | 172 | Get Quote |
![]() ![]() |
25MG | 333 | Get Quote |
![]() ![]() |
50MG | 587 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameUNC2025 2HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionUNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
-
DescriptionUNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorMer|Flt3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight549.62
-
Molecular FormulaC28H42Cl2N6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.Cl.OC1CCC(CC1)n3cc(c2cnc(NCCCC)nc23)c4ccc(cc4)CN5CCN(C)CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
RBN-3143
RBN-3143 is a potent inhibitor of NAD+-competitive catalytic PARP14 (IC50= 4 nM), which inhibits ADP-ribosylation mediated by PARP14 and stabilizes PARP14 in cell lines, demonstrating research potential for lung inflammation.
-
Rucaparib Camsylate
Rucaparib Camsylate is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains. Rucaparib is the most effective PARP inhibitor in enzyme assays (Ki: 1.4 nM). Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilized D283Med cells.
-
Desmethyl-VS-5584
Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.